LONDON, Nov. 17, 2016 /PRNewswire/ -- Polymerase Chain Reaction (PCR) Holds Close to 53% Share but Strong Clinical Research will Push NGS to Revolutionize this Space in the Next 5 to 10 Years
The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher dominate in this field and are expected to maintain their positions in the market through mergers and acquisitions of smaller start-ups. Illumina maintains its monopoly in the NGS market followed by Thermo Fisher, which is likely to remain unchanged during the forecast years. The market continues to grow despite strict guidelines. Molecular diagnostics is expected to at least partially replace microbiology testing and other ELISA/ immunoassay based tests during the forecast years. This study discusses growth opportunities and trends and offers predictions for the 4 technology segments discussed above. Trends across therapeutic areas such as oncology, women's health, HIV/STDs, and infectious disease testing areas are also covered in this research. The study period is 2014 to 2021.
Key questions this study answers:
Will the molecular diagnostics market disrupt your current business or create growth opportunities? What do you need to know?
Where are the hottest segments in this market? Where is the most interest in terms of funding and innovation?
What are some of the most disruptive products by disease indication in this space?
What are the gaps in the market that encourage penetration and provide opportunities to new entrants?
Download the full report: https://www.reportbuyer.com/product/4331991/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers